This study presents the conceptual rationale and development plan for a multi-component nutraceutical approach designed in capsule form, which addresses the bidirectional interaction between the stress response, glycemic regulation, immune response, and gut microbiota through multiple axes rather than a single target. The proposed composition consists of hesperidin, standardized Rhodiola rosea extract, chromium picolinate, zinc bisglycinate, microencapsulated Lactobacillus rhamnosus GG, and inulin. Component selection was guided by the principles of (i) biological plausibility with target axes, (ii) safety and tolerability, (iii) potential complementarity/synergy, and (iv) technical feasibility within a size 0 capsule volume. Doses were determined by jointly evaluating the usage ranges reported in clinical and preclinical literature, safety thresholds, and formulation constraints, resulting in an initial design that does not claim clinical efficacy and is suitable for further validation studies.